Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as siRNA that target ApoC3 and ANGPTL3 expression, lipid particles comprising one or more (e.g., a combination) of the therapeutic nucleic acids, and methods of delivering and/or administering the lipid particles (e.g., for treating hypertriglyceridemia in humans).
Type:
Application
Filed:
April 16, 2020
Publication date:
February 18, 2021
Applicant:
ARBUTUS BIOPHARMA CORPORATION
Inventors:
Ting CHIU, Narayanan HARIHARAN, Amy C. H. LEE, Christopher Justin PASETKA, Janet Ruth PHELPS, Nicholas Michael SNEAD, Andrew Anthony WIECZOREK
Abstract: The present invention includes in one aspect substituted 2-oxo-1,2,5,6-tetrahydrobenzo[h]quinoline-3-carboxylic acids, analogues thereof, and compositions comprising the same, which can be used to treat and/or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) in a patient.
Type:
Application
Filed:
March 11, 2019
Publication date:
January 21, 2021
Applicant:
Arbutus Biopharma Corporation
Inventors:
Shuai Chen, Bruce D. Dorsey, Yi Fan, Dimitar B. Gotchev, Jorge Quintero
Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).
Type:
Application
Filed:
April 10, 2018
Publication date:
December 31, 2020
Applicant:
ARBUTUS BIOPHARMA CORPORATION
Inventors:
James HEYES, Richard J. HOLLAND, Adam JUDGE, Amy C. H. LEE, Alan D. MARTIN, Nicholas Michael SNEAD, Emily P. THI, Mark WOOD, Xin YE
Abstract: Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.
Type:
Application
Filed:
December 13, 2019
Publication date:
November 19, 2020
Applicant:
Arbutus Biopharma Corporation
Inventors:
Muthiah Manoharan, Kallanthottathil G. Rajeev, Akin Akinc, Jayaprakash K. Nair, Muthusamy Jayaraman, Martin Maier
Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.
Type:
Grant
Filed:
August 8, 2017
Date of Patent:
November 17, 2020
Assignee:
ARBUTUS BIOPHARMA CORPORATION
Inventors:
Muthiah Manoharan, Kallanthottathil G. Rajeev, David Butler, Jayaprakash K. Nair, Muthusamy Jayaraman, Laxman Eltepu
Abstract: The present invention includes substituted pyridinone-containing tricyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection in a patient. In certain embodiments, the compounds and compositions of the invention inhibit and/or reduce HBsAg secretion.
Type:
Grant
Filed:
November 3, 2017
Date of Patent:
November 3, 2020
Assignee:
Arbutus Biopharma Corporation
Inventors:
Laurèn Danielle Bailey, Yingzhi Bi, Shuai Chen, Bruce D. Dorsey, Dimitar B. Gotchev, Richard James Holland, Ramesh Kakarla, Duyan Nguyen, Mark Christopher Wood
Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.
Type:
Grant
Filed:
September 6, 2018
Date of Patent:
November 3, 2020
Assignee:
ARBUTUS BIOPHARMA CORPORATION
Inventors:
Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu
Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses.
Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The lipid particles comprise a cationic lipid, a non-cationic lipid, and an mRNA molecule that is encapsulated within the lipid particle. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provides cationic lipids that are useful for preparing the compositions of the invention.
Type:
Application
Filed:
February 24, 2020
Publication date:
September 24, 2020
Applicant:
ARBUTUS BIOPHARMA CORPORATION
Inventors:
James HEYES, Lorne R. PALMER, Stephen P. REID, Edward D. YAWORSKI, Ian MACLACHLAN, Mark WOOD, Alan D. MARTIN
Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
Abstract: The present invention includes substituted pyridinone-containing tricyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection in a patient. In certain embodiments, the compounds and compositions of the invention inhibit and/or reduce HBsAg secretion.
Type:
Application
Filed:
March 30, 2020
Publication date:
August 20, 2020
Applicant:
Arbutus Biopharma Corporation
Inventors:
Laurèn Danielle Bailey, Yingzhi Bi, Shuai Chen, Bruce D. Dorsey, Dimitar B. Gotchev, Richard James Holland, Ramesh Kakarla, Duyan Nguyen, Mark Christopher Wood
Abstract: The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
Type:
Grant
Filed:
August 28, 2015
Date of Patent:
May 19, 2020
Assignees:
THE UNIVERSITY OF BRITISH COLUMBIA, ARBUTUS BIOPHARMA CORPORATION
Inventors:
Michael J. Hope, Sean C. Semple, Jianxin Chen, Thomas D. Madden, Pieter R. Cullis, Marco A. Ciufolini, Barbara Low Shoud Mui
Abstract: Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is Also disclosed are methods of producing the cationic lipid of formula (I).
Type:
Application
Filed:
October 4, 2019
Publication date:
May 7, 2020
Applicant:
Arbutus Biopharma Corporation
Inventors:
Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Michael E. Jung
Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses.
Abstract: The present invention includes novel substituted 1-hydroxy-pyridin-2(1H)-ones, which can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention inhibit HBV RNAse H activity.
Abstract: The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors.
Type:
Application
Filed:
March 20, 2018
Publication date:
January 23, 2020
Applicant:
Arbutus Biopharma Corporation
Inventors:
Andrew G. Cole, Bruce D. Dorsey, Ramesh Kakarla, Steven Kultgen, Jorge Quintero
Abstract: Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is Also disclosed are methods of producing the cationic lipid of formula (I).
Type:
Grant
Filed:
May 12, 2017
Date of Patent:
October 29, 2019
Assignee:
Arbutus Biopharma Corporation
Inventors:
Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Michael E. Jung